Hillsdale Investment Management Inc. Denali Therapeutics Inc. Transaction History

Hillsdale Investment Management Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$25.97 - $38.53 $667,429 - $990,221	25,700 New	25,700 $789,000
Q3 2021 Oct 21, 2021	SELL	$48.48 - $78.23 $833,856 - $1.35 Million	-17,200 Closed	0 $0
Q2 2021 Jul 29, 2021	SELL	$50.3 - $78.44 $50,300 - $78,440	-1,000 Reduced 5.49%	17,200 $1.35 Million
Q1 2021 Apr 22, 2021	BUY	$53.8 - $81.53 $979,160 - $1.48 Million	18,200 New	18,200 $1.04 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hillsdale Investment Management Inc. with notifications on news.